Top

International Journal of Colorectal Disease

Published in:

01-05-2010 | Original Article

Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases

Authors: Alfred Balasa, Grace Gathungu, Peter Kisfali, E O’Brian Smith, Judy H. Cho, Bela Melegh, Richard Kellermayer

Published in: International Journal of Colorectal Disease | Issue 5/2010

Abstract

Background and aims

A 5-bp insertion–deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested.

Methods

Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn’s disease, 20 ulcerative colitis) PBL samples.

Results

The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD.

Conclusions

These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.

Reik W (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447:425–432CrossRefPubMed

Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597–610CrossRefPubMed

Kerkel K, Spadola A, Yuan E et al (2008) Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40:904–908CrossRefPubMed

Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117CrossRefPubMed

Moser D, Ekawardhani S, Kumsta R et al (2009) Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology 34:458–467CrossRefPubMed

Wang H, Ogawa M, Wood JR et al (2008) Genetic and epigenetic mechanisms combine to control MMP1 expression and its association with preterm premature rupture of membranes. Hum Mol Genet 17:1087–1096CrossRefPubMed

Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517CrossRefPubMed

Sathiyasekaran M, Shivbalan S (2006) Crohn's disease. Indian J Pediatr 73:723–729CrossRefPubMed

Petronis A (2006) Epigenetics and twins: three variations on the theme. Trends Genet 22:347–350CrossRefPubMed

10.

Biank V, Broeckel U, Kugathasan S (2007) Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis 13:1430–1438CrossRefPubMed

11.

Petronis A, Petroniene R (2000) Epigenetics of inflammatory bowel disease. Gut 47:302–306CrossRefPubMed

12.

Tahara T, Shibata T, Nakamura M et al (2009) Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int J Mol Med 23:521–527CrossRefPubMed

13.

Tahara T, Shibata T, Nakamura M et al (2009) Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med 9:125–130CrossRefPubMed

14.

Dideberg V, Kristjansdottir G, Milani L et al (2007) An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 16:3008–3016CrossRefPubMed

15.

Sigurdsson S, Goring HH, Kristjansdottir G et al (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17:872–881CrossRefPubMed

16.

Brandeis M, Frank D, Keshet I et al (1994) Sp1 elements protect a CpG island from de novo methylation. Nature 371:435–438CrossRefPubMed

17.

Magyari L, Farago B, Bene J et al (2007) No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn's disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol 13:2205–2208PubMed

18.

Waterland RA, Jirtle RL (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23:5293–5300CrossRefPubMed

19.

Shen L, Guo Y, Chen X, Ahmed S, Issa JP (2007) Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 42:48–52CrossRefPubMed

20.

Colella S, Shen L, Baggerly KA, Issa JP, Krahe R (2003) Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146–150PubMed

21.

Bock C, Walter J, Paulsen M, Lengauer T (2008) Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping. Nucleic Acids Res 36:e55CrossRefPubMed

22.

Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagnostics 9:368–381CrossRef

23.

Gazzoli I, Kolodner RD (2003) Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 23:7992–8007CrossRefPubMed

Title: Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases
Authors: Alfred Balasa
Grace Gathungu
Peter Kisfali
E O’Brian Smith
Judy H. Cho
Bela Melegh
Richard Kellermayer
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 5/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-0874-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases

Abstract

Background and aims

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2010

Diagnosing lower gastrointestinal tuberculosis: colonoscopy is essential

Role of TGF-β1, its receptor TGFβRII, and Smad proteins in the progression of colorectal cancer

Subcutaneous Redon drains do not reduce the incidence of surgical site infections after laparotomy. A randomized controlled trial on 200 patients

An endoscopic training model to improve accuracy of colonic polyp size measurement

Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence

Comparison of immunologic outcomes of laparoscopic vs open approaches in clinical stage III colorectal cancer